Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal hepatitis B revaccination with topical imiquimod in cirrhotic non-responders
2021-000644-22Phase 2Active
- Sponsor
- CHRU Nancy
- Start
- Jul 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Hepatitis B vaccine and imiquimod in hepatitis B (HBV) (3 arms), sponsored by CHRU Nancy. Primary endpoint: Seroprotection at month 7. Started Jul 2021; status: active.
02
Drugs
Hepatitis B vaccineimiquimod
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2021-000644-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000644-22.